PREDICT Plus: development and validation of a prognostic\ud model for early breast cancer that includes HER2.

Article English OPEN
Wishart, G.C. ; Bajdik, C.D. ; Dicks, E. ; Provenzano, E. ; Schmidt, M.K. ; Sherman, M. ; Greenberg, D.C. ; Green, A.R. ; Gelmon, K.A. ; Kosma, V.M. ; Olson, J.E. ; Beckmann, M.W. ; Winqvist, R. ; Cross, S.S. ; Severi, G. ; Huntsman, D. ; Pylkäs, K. ; Ellis, I. ; Nielsen, T.O. ; Giles, G. ; Blomqvist, C. ; Fasching, P.A. ; Couch, F.J. ; Rakha, E. ; Foulkes, W.D. ; Blows, F.M. ; Bégin, L.R. ; van't Veer, L.J. ; Southey, M. ; Nevanlinna, H. ... view all 37 authors
  • Publisher: Cancer Research UK
  • Subject:
    mesheuropmc: skin and connective tissue diseases

Background: Predict (www.predict.nhs.uk) is an online, breast cancer prognostication and treatment benefit tool. The aim of this\ud study was to incorporate the prognostic effect of HER2 status in a new version (Predict þ ), and to compare its performance with the\ud original Predict and Adjuvant!.\ud Methods: The prognostic effect of HER2 status was based on an analysis of data from 10 179 breast cancer patients from 14 studies in\ud the Breast Cancer Association Consortium. The hazard ratio estimates were incorporated into Predict. The validation study was\ud based on 1653 patients with early-stage invasive breast cancer identified from the British Columbia Breast Cancer Outcomes Unit.\ud Predicted overall survival (OS) and breast cancer-specific survival (BCSS) for Predict þ , Predict and Adjuvant! were compared with\ud observed outcomes.\ud Results: All three models performed well for both OS and BCSS. Both Predict models provided better BCSS estimates than\ud Adjuvant!. In the subset of patients with HER2-positive tumours, Predict þ performed substantially better than the other two models\ud for both OS and BCSS.\ud Conclusion: Predict þ is the first clinical breast cancer prognostication tool that includes tumour HER2 status. Use of the model\ud might lead to more accurate absolute treatment benefit predictions for individual patients.
  • References (35)
    35 references, page 1 of 4

    Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW (2007a) Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 43(10): 1548-1555

    Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, Haybittle JL (2007b) Reading the prognosis of the individual with breast cancer. Eur J Cancer 43(10): 1545-1547

    Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7(5): e1000279

    Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 12(8): 2468-2475

    Campbell HE, Taylor MA, Harris AL, Gray AM (2009) An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101(7): 1074-1084

    Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K (2008) Human epidermal growth factor receptor 2 verexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26(35): 5697-5704

    Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus-Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N, Zatonski W, Bardin-Mikolajczak A, Struewing JP (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119(4): 376-388

    Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156: 69-70

    Hartikainen JM, Tuhkanen H, Kataja V, Dunning AM, Antoniou A, Smith P, Arffman A, Pirskanen M, Easton DF, Eskelinen M, Uusitupa M, Kosma VM, Mannermaa A (2005) An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found. Cancer Epidemiol Biomarkers Prev 14(1): 75-80

    Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K (1982) A prognostic index in primary breast cancer. Br J Cancer 45(3): 361-366

  • Related Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark